IMMvention Therapeutix
Jessica Sorrentino is an accomplished biopharmaceutical leader with extensive experience in research and development across multiple organizations. Currently serving as Founder and President of Zimmertino, LLC, and CSO/Head of Research and Development at IMMvention Therapeutix, Inc., Jessica is focused on innovative therapies for sickle cell disease. Previously, Jessica held senior positions at Ribometrix Inc., TrpBlue, Inc., Istari Oncology, and G1 Therapeutics, contributing to the development of novel small molecule medicines and immuno-oncology platforms. Educational qualifications include a PhD in Toxicology from the University of North Carolina at Chapel Hill and a B.S. in Molecular Genetics from the University of Rochester.
This person is not in any teams
IMMvention Therapeutix
IMMvention is developing therapies that inhibit multiple inflammasome pathways that result in increased cytokine production that is at the root cause of some of the following diseases.